Anavex Life Sciences Corp (AVXL)

[georgejjl]

LB19 - Novel analytics framework for augmenting single-arm Phase 2a open label trials with Real-World external control data:
Application to the Blarcamesine (ANAVEX®2-73) study in Alzheimer’s disease matched with propensity corrected patients from Alzheimer’s Disease Neuroimaging Initiative (ADNI) exploring treatment effect on cognition at Interim two-year (104-Week) timepoint

Mohammad Afshar (1), Coralie Williams (1), Nanthara Sritharan (1), Frederic Parmentier (1), Federico Goodsaid (2),
Christopher Missling (3)
(1) Ariana Pharma, France, (2) Regulatory Pathfinders, United States, (3) Anavex, United States

P90: Gut Microbiota and Response to Blarcamesine (ANAVEX2- 73) in Alzheimer’s Disease Patients: Abundance of Lachnospiraceae and Enterobacteriaceae Families as Potential Biomarker of Response from a 2-Year Study Interim Clinical Data Analysis using KEM Artific

Mohammad AFSHAR (1), Coralie WILLIAMS (1), Frederic PARMENTIER (1), Adrien ETCHETO (1), Christopher MISSLING (2) - (1)Ariana Pharma, France, (2)Anavex, United States

P99: Levels of gut microbiota potentially regulated through anti-inflammatory effect identified as associated to response to Blarcamesine (ANAVEX2-73) in Alzheimer’s disease patients in 2-year Interim clinical data using KEM Artificial Intelligence analysis

Mohammad AFSHAR (1), Coralie WILLIAMS (1), Frederic PARMENTIER (1), Adrien ETCHETO (1), Christopher MISSLING (2) - (1)Ariana Pharma, France, (2)ANAVEX, United States

https://www.ctad-alzheimer.com/theme-4-clinical-trials-biomarkers

Good luck and GOD bless,